2 results
Approved WMORecruiting
Primary: • Demonstrate superior efficacy (increased progression-free survival [PFS]) of MEK162 vs. physician*s choice of selected chemotherapies (liposomal doxorubicin, paclitaxel and topotecan)Key Secondary: • Demonstrate superior efficacy (…
Approved WMORecruiting
Hypothesis:Using PlasmaJet Surgical Device during surgery improves the rate of complete cytoreductive surgery in women with advanced ovarian cancer.Primary research question:Does the use of PlasmaJet technique result in an increased number of…